A series of randomized, placebo-controlled n-of-1 trials (a randomized trial in individual patients) found no overall effect of atorvastatin 20 mg on muscle symptoms compared with placebo in participants who had previously reported severe muscle symptoms when taking statins. A total of 200 participants who had recently stopped or were considering stopping treatment with statins because of muscle symptoms were randomized to a sequence of 6 double blinded treatment periods (two months each) of atorvastatin 20 mg daily or placebo. 151 participants provided symptoms scores for at least one statin period and one placebo period and were included in the primary analysis. Overall, no difference in muscle symptom scores was found between the statin and placebo periods. Withdrawals because of intolerable muscle symptoms were 18 participants (9%) during a statin period and 13 (7%) during a placebo period. Two thirds of those completing the trial reported restarting long-term treatment with statins. The findings are in line with previous and concurrent studies and suggest a nocebo effect since most patients taking statins did not experience symptoms causally related to their statin. However, a causal link between statins and rare risk of myopathy, even severe rhabdomyolysis is well characterized. Source: https://www.bmj.com/
Early-life sugar restriction during pregnancy and infancy was associated with a 34% lower risk of…
Higher levels of physical activity were associated with lower risks of all-cause dementia, Alzheimer’s disease,…
In US adults aged ≥65 years, overweight and class I–II obesity were associated with lower…
In community-dwelling older adults without prior cardiovascular disease (CVD), new or persistent heart stress (HS)—defined…
In the German multicenter study of 5,521 patients with colorectal cancer (CRC), the apparent survival…
In adults aged 75 years or older without a history of atherosclerotic cardiovascular disease (ASCVD)…
This website uses cookies.